Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): A multicenter, open-label study

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 4, 2009, Pages 410-417

  Wykrzykowska, Joanna J ^a   Warnholtz, Ascan ^b   de Jaeger, Peter ^a   Curzen, Nick ^c   Oldroyd, Keith G ^d   Collet, Jean Philippe ^e   Ten Berg, Jurrien M ^f   Rademaker, Tessa ^g   Goedhart, Dick ^g   Lissens, Jurgen ^h   Kint, Peter Paul ^g   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d WESTERN INFIRMARY   (United Kingdom)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f ST ANTONIUS HOSPITAL   (Netherlands)

^g CARDIALYSIS   (Netherlands)

^h BRISTOL MYERS SQUIBB   (United States)

Author keywords

Clopidogrel cessation; Drug eluting stent; Inflammation; Platelet inhibition

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CD40 LIGAND; CLOPIDOGREL; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; PADGEM PROTEIN; RAPAMYCIN; ZOTAROLIMUS;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CD40 LIGAND; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; TICLOPIDINE; TIME FACTORS;

EID: 70350550067     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0354-y     Document Type: Article

References (28)

1. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, De Lago A, Wilmer C et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 288(19):2411-2420. doi: 10.1001/jama.288.19.2411
2. Berger PB, Steinhubl S (2002) Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: A US perspective. Circulation 106(17):2284-2287. doi: 10.1161/01.CIR.0000035924.70846.20
3. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A et al (2007) Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 370(9591):937-948. doi: 10.1016/S0140-6736(07)61444-5
4. Costa MA, Angiolillo DJ, Tannenbaum M, Driesman M, Chu A, Patterson J et al (2008) Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial). Am J Cardiol 101(12):1704-1711. doi: 10.1016/j.amjcard.2008.02.053
5. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK et al (2007) Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 27(7):1500-1510. doi: 10.1161/ ATVBAHA.107.144220
6. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17):2126-2130. doi: 10.1001/jama.293.17.2126
7. Ho PM, Peterson ED, Wang L, Magid DJ, Fihn SD, Larsen GC et al (2008) Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 299(5):532-539. doi: 10.1001/jama.299.5.532
8. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P et al (2006) Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 55(3):780-784. doi: 10.2337/ diabetes.55.03.06.db05-1394
9. Saw J, Madsen EH, Chan S, Maurer-Spurej E (2008) The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol 52(23):1826-1833. doi: 10.1016/ j.jacc.2008.08.047
10. Angiolillo DJ, Costa MA, Shoemaker SB, Desai B, Bernardo E, Suzuki Y et al (2008) Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am J Cardiol 101(4):440-445. doi: 10.1016/j.amjcard.2007.09.087
11. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F et al (2006) A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 27(22):2667-2674. doi: 10.1093/ eurheartj/ehl334
12. Xiao Z, Theroux P (2004) Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 43(11):1982-1988. doi: 10.1016/j.jacc.2003.10.071
13. Aggarwal A, Blum A, Schneider DJ, Sobel BE, Dauerman HL (2004) Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. Coron Artery Dis 15(8):471-475. doi: 10.1097/ 00019501-200412000-00003
14. Vivekananthan DP, Bhatt DL, Chew DP, Zidar FJ, Chan AW, Moliterno DJ et al (2004) Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 94(3):358-360. doi: 10.1016/j.amjcard.2004.04.035
15. Furman MI, Krueger LA, Linden MD, Fox ML, Ball SP, Barnard MR et al (2005) GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost 3(2):312-320. doi: 10.1111/ j.1538-7836.2005.01124.x
16. Nannizzi-Alaimo L, Alves VL, Phillips DR (2003) Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 107(8):1123-1128. doi: 10.1161/01.CIR.0000053559.46158.AD
17. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM et al (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348(12):1104-1111. doi: 10.1056/NEJMoa022600
18. Rinder HM, Bonan JL, Rinder CS, Ault KA, Smith BR (1991) Dynamics of leukocyte-platelet adhesion in whole blood. Blood 78(7):1730-1737
19. Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Luscher TF (2007) Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 12(2):113-122. doi: 10.1177/1358863X07077462
20. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA (2007) Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? J Am Coll Cardiol 49(6):657-666. doi: 10.1016/j.jacc.2006.10.050
21. Gurbel PA, Bliden KP, Guyer K, Aggarwal N, Tantry US (2007) Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res 119(5):563-570. doi: 10.1016/j.thromres.2006.05.006
22. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP et al (2005) Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 46(10):1820-1826. doi: 10.1016/j.jacc.2005.07.041
23. Yip HK, Chang LT, Sun CK, Yang CH, Hung WC, Cheng CI et al (2006) Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. Am J Cardiol 97(2):192-194. doi: 10.1016/j.amjcard.2005.08.023
24. Gurbel PA, Bliden KP, Tantry US (2006) Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: Results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol 48(11):2186-2191. doi: 10.1016/ j.jacc.2005.12.084
25. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R (2007) The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 100(8B):36M-44M. doi: 10.1016/ j.amjcard.2007.08.020
26. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC et al (2007) Drug-eluting stent and coronary thrombosis: Biological mechanisms and clinical implications. Circulation 115(8):1051-1058. doi: 10.1161/ CIRCULATIONAHA.106.675934
27. Azar RR, Kassab R, Zoghbi A, Aboujaoude S, El-Osta H, Ghorra P et al (2006) Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 151(2):521 e1-521 e4
28. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359(21):2195-2207. doi: 10.1056/NEJMoa0807646